anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to an econazole nitrate vagina soft capsule and a preparation method thereof. The econazole nitrate vagina soft capsule includes a soft capsule skin which is filled with contents. The contents include, by weight, 50 parts of econazole nitrate, 250-350 parts of white Vaseline, 25 parts of bee wax and 325-425 parts of light-weight liquid paraffin. The soft capsule skin includes, by weight, 1 part of gelatin, 0.6 parts of glycerin, 1 part of water and 0.008 parts of a light screening agent. The econazole nitrate vagina soft capsule can be stored and transported at room temperature, is convenient to store and is ensured in quality and usage. The soft capsule contains the light screening agent, so that the econazole nitrate is prevented from changing due to contact with light during storage and transportation, thereby ensuring stability of the econazole nitrate.
<P>PROBLEM TO BE SOLVED: To provide a composition and a method for treating ischemia, and a molecule related to hibernation states.  <P>SOLUTION: There are disclosed the composition and method for treating ischemia, and the molecule related to hibernation states; namely, a method for evaluating hibernation states of animals at various time points during the hibernation period is disclosed. Also a fact is disclosed in the specification that the dormant animal is liable to survive while coming to wakefulness in the initial stage and the late stage of hibernation, not in the medium stage thereof. Further a fact is disclosed that the plasma fraction obtained from the dormant animal in the initial stage of hibernation, not in the medium stage thereof, exerts influence on the ischemia in a rat model, and contains molecules usable for treating ischemia. These molecules are indicated to contain FPA (fibrinogen A) and derivatives thereof, and bradykinin and derivatives thereof, in the specification.  <P>COPYRIGHT: (C)2010,JPO&INPIT
Fluctuations in MS symptoms in women with RR-MS might be affected by a variety of factors. To determine which factors are important, we are asking subjects to fill out a diary and calendar on a daily basis for 90 days. After an initial instructional meeting over the phone, the materials are filled out at home and returned monthly via postage-paid envelopes provided by the study. Compensation ($10 gift card) is sent after each monthly diary is received. The diary includes a list of symptoms and a rank scale for the women to show subtle changes in MS symptoms. The calendar allows the subject to denote additional factors such as stress, hormonal cycles, illnesses or immunizations and changed or missed medications. We anticipate that statistical analysis will reveal which of these factors affect women with relapsing-remitting multiple sclerosis.
Participants received 5 consecutive days of accelerated cTBSmod to the right frontal pole. Each cTBSmod session was comprised of 1800 pulses, delivered in a continuous train of 600 bursts. Each burst contained 3 pulses at 30 Hz, repeated at 6 Hz. Ten sessions were applied per day (18,000 pulses/day, hourly) (90,000 total pulses) using a Magventure Magpro X100. Stimulation was delivered at 90% resting motor threshold (depth corrected). Localite Neuronavigation System was used to position the TMS coil over the individualized stimulation target.
Sixteen subjects in 2 cohorts (8 subjects per cohort) will be dosed on 4 occasions. Within each cohort, 4 subjects will be randomised to active dosing with CRH with desmopressin, GHRH and OGTT challenge and 4 subjects will be randomised to placebo dosing with CRH with desmopressin, GHRH and OGTT challenge.
Methods, apparatus, and systems are provided for tracking freight. Embodiments include a tracking device for a trailer containing a load. The tracking device includes a support member, a connector, a housing and a GPS tracker configured to track the location of the load. The connector securely attaches to a container on the trailer and attaches to a seal such that the container cannot be opened without breaking the seal. The support member stabilizes the housing and protects the tracking device during transit of the load. A tracking system may implement to monitor, gather information and report on the tracking device and the load.
FIELD: chemical engineering. SUBSTANCE: method involves carrying out quantitatively measuring analytes presence in liquid and solid state phases by measuring residual magnetic induction by using chemical compounds suitable for these purposes. First of all, all substances of specific structure are labeled with ferrimagnetic or ferromagnetic markers. Then, the magnetically marked substances of specific structure are added to sample under measurement. The sample under measurement is magnetized by means of magnetic field of corresponding intensity applied from outside. Residual magnetic induction of magnetized colloid particles is measured by means of magnetic field sensory members. Residual magnetic induction generated due to specific binding and its magnitude are subjected to study. The substances used by the method are ferrimagnetic or ferromagnetic substances are stable or quasi- stable particles of ferric oxides, barium ferrite, strontium ferrite, pure iron, chrome dioxide, nickel, cobalt and ferric oxides with manganese, copper or cobalt adds. EFFECT: high accuracy in detecting presence of analytes; simplified analysis method. 31 cl, 2dwg
A termite bait includes a plurality of cellulosic food material pieces palatable to termites embedded within a water resistant polyurethane foam matrix. Another termite bait includes a plurality of cellulosic food material pieces embedded within a water-absorbent polyurethane foam matrix. Yet another termite bait includes at least one cellulosic food material piece encapsulated within a water resistant polyurethane foam coating. Such termite baits can be used alone or in a monitoring device or other termite control device. Another termite control device includes a container, a cellulosic food material within the container and a water resistant polyurethane foam positioned to separate the food material from its environment. The container can contain a termite bait as described above or can include a chamber containing a cellulosic food material and at least one pocket containing a polyurethane foam barrier to reduce intrusion of water through the pocket to the food material.
This study is a prospective interventional cohort in clinically quiescence IBD patients in Siriraj Hospital, Mahidol University, Bangkok, Thailand. At enrollment, clinical information, dietary intake, inflammatory markers, and fecal microbiota will be recorded. Dietary intake will be assessed by an experienced nutritionist using pictures of food, a dietary questionnaire, and patient interviewing. The nutritionist advises the participants to consume a semi-vegetarian diet which includes high dietary fiber consumption and low red meat and processed food consumption. All patients will be required to send all pictures of food intake three days in 1 week before every visit, including two weekdays and one weekend. The dietary component will be analyzed using Nutrient calculation computer software INMUCAL-Nutrient V3 database NB1 (Institute of Nutrition, Mahidol University. Nakornpathom. 2013). The study will take 1 year including 6 visits (including baseline, 6th weeks, 18th week, 30th week, 42nd week, 54th week) for each patient. The primary outcome is the effect of increasing fiber diets and decreasing red meat and processed food on maintaining clinical remission in IBD. Secondary outcomes are the effect of modifying diet on change of inflammatory markers, microbiota, and quality of life.
Amlodipine

No evidence of teratogenicity or other embryo/fetal toxicity was found when pregnant rats and rabbits were treated orally with amlodipine maleate at doses of up to 10 mg amlodipine/kg/day (respectively, about 10 and 20 times the MRHD of 10 mg amlodipine on a mg/m2 basis) during their respective periods of major organogenesis. (Calculations based on a patient weight of 60 kg.) However, litter size was significantly decreased (by about 50%) and the number of intrauterine deaths was significantly increased (about 5-fold) for rats receiving amlodipine maleate at a dose equivalent to 10 mg amlodipine/kg/day for 14 days before mating and throughout mating and gestation. Amlodipine maleate has been shown to prolong both the gestation period and the duration of labor in rats at this dose. There are no adequate and well-controlled studies in pregnant women. Amlodipine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. 

Valsartan 

No teratogenic effects were observed when valsartan was administered to pregnant mice and rats at oral doses of up to 600 mg/kg/day and to pregnant rabbits at oral doses of up to 10 mg/kg/day. However, significant decreases in fetal weight, pup birth weight, pup survival rate, and slight delays in developmental milestones were observed in studies in which parental rats were treated with valsartan at oral, maternally toxic (reduction in body weight gain and food consumption) doses of 600 mg/kg/day during organogenesis or late gestation and lactation. In rabbits, fetotoxicity (i.e., resorptions, litter loss, abortions, and low body weight) associated with maternal toxicity (mortality) was observed at doses of 5 and 10 mg/kg/day. The no observed adverse effect doses of 600, 200, and 2 mg/kg/day in mice, rats and rabbits, respectively, are about 9, 6, and 0.1 times the MRHD of 320 mg/day on a mg/m2 basis. (Calculations based on a patient weight of 60 kg.) 

Amlodipine Besylate and Valsartan 

In the oral embryofetal development study in rats using amlodipine besylate plus valsartan at doses equivalent to 5 mg/kg/day amlodipine plus 80 mg/kg/day valsartan, 10 mg/kg/day amlodipine plus 160 mg/kg/day valsartan, and 20 mg/kg/day amlodipine plus 320 mg/kg/day valsartan, treatment-related maternal and fetal effects (developmental delays and alterations noted in the presence of significant maternal toxicity) were noted with the high dose combination. The no-observed-adverse-effect level (NOAEL) for embryofetal effects was 10 mg/kg/day amlodipine plus 160 mg/kg/day valsartan. On a systemic exposure [AUC(0-∞)] basis, these doses are, respectively, 4.3, and 2.7 times the systemic exposure [AUC(0-∞)] in humans receiving the MRHD (10/320 mg/60 kg).
The initial clinical studies of COREG CR in patients with hypertension, heart failure, and left ventricular dysfunction following myocardial infarction did not include sufficient numbers of subjects 65 years of age or older to determine whether they respond differently from younger patients.

A randomized study (n = 405) comparing mild to severe heart failure patients switched to COREG CR or maintained on immediate-release carvedilol included 220 patients who were 65 years of age or older. In this elderly subgroup, the combined incidence of dizziness, hypotension, or syncope was 24% (18/75) in patients switched from the highest dose of immediate-release carvedilol (25 mg twice daily) to the highest dose of COREG CR (80 mg once daily) compared to 11% (4/36) in patients maintained on immediate-release carvedilol (25 mg twice daily). When switching from the higher doses of immediate-release carvedilol to COREG CR, a lower starting dose is recommended for elderly patients [see Dosage and Administration (2.5)].

The following information is available for trials with immediate-release carvedilol. Of the 765 patients with heart failure randomized to carvedilol in US clinical trials, 31% (235) were 65 years of age or older, and 7.3% (56) were 75 years of age or older. Of the 1,156 patients randomized to carvedilol in a long-term, placebo-controlled trial in severe heart failure, 47% (547) were 65 years of age or older, and 15% (174) were 75 years of age or older. Of 3,025 patients receiving carvedilol in heart failure trials worldwide, 42% were 65 years of age or older. Of the 975 myocardial infarction patients randomized to carvedilol in the CAPRICORN trial, 48% (468) were 65 years of age or older, and 11% (111) were 75 years of age or older. Of the 2,065 hypertensive patients in US clinical trials of efficacy or safety who were treated with carvedilol, 21% (436) were 65 years of age or older. Of 3,722 patients receiving immediate-release carvedilol in hypertension clinical trials conducted worldwide, 24% were 65 years of age or older.

With the exception of dizziness in hypertensive patients (incidence 8.8% in the elderly versus 6% in younger patients), no overall differences in the safety or effectiveness (see Figures 2 and 4) were observed between the older subjects and younger subjects in each of these populations. Similarly, other reported clinical experience has not identified differences in responses between the elderly and younger subjects, but greater sensitivity of some older individuals cannot be ruled out.
The present invention relates to a novel antibody to CD80 and CD86 used to prevent or to treat rheumatoid arthritis. According to the present invention, the antibody is is an antibody that specifically combines to CD80n and/or CD86 overexpressed in a cell. According to the present invention, the antibody has very low homology in comparison with a CDR sequence of conventional CD80 and/or CD86 target antibodies. So, the sequence of antibody has uniqueness. According to the present invention, the antibody has equivalent ability to inhibit T-cell activity performance compared with abatacept used in the conventional treatment of rheumatoid arthritis when treated alone and has the remarkably excellent ability to inhibit T-cell activity performance in comparison with the abatacept when treated in combination with the CD80 target antibody and CD86 target antibody. Also, the antibody of the present invention is very effective in the prevention or the treatment of rheumatoid arthritis.
INTRODUCTION: Worldwide, it has been reported that fully vaccinated people still die of COVID-19-associated symptoms, generating public uncertainty about the safety and effectiveness of the vaccines. Hence, this research is aimed at assessing the incidence of COVID-19 breakthrough infection among vaccinated Health Workers and the possible effect of changes in the practice of post-vaccination safety precautions.
METHOD: This was a Health facility-based descriptive cross-sectional study. Data were collected using self-administered questionnaires distributed at the participant's work unit across the selected health facilities. The nasopharyngeal specimen was also obtained from the participants and analysed using STANDARD Q COVID-19 Ag Test rapid chromatographic immunoassay for the detection of antigens to SARS-CoV-2. All data were input and analyzed using SPSS version 20.
RESULTS: There was a statistically significant relationship between the vaccination status of respondents and the post-vaccination test result (χ2 = 6.816, df = 1, p = 0.009). The incidence of COVID-19 infection among the vaccinated and unvaccinated HCWs was 2% and 8% respectively. 5 of the 15 respondents who tested positive for COVID-19 had been fully vaccinated. However, all 5 of them did not practice safety measures after vaccination. None of the respondents who practised safety measures after vaccination tested positive for COVID-19. The remaining 10 respondents that tested positive for COVID-19 had not been vaccinated though they practised safety precautions.
CONCLUSION: Vaccination and the practice of safety precautions will go a long way to preventing future COVID-19 breakthrough infections.
Subjects will be given the option to undergo the comprehensive rehabilitation program including speech therapy and physical therapy. Progression through the rehabilitation program will be personalized and designed based on impairments identified during the comprehensive baseline assessment and previous sessions. Subjects will undergo 12 one- hour sessions over the course of six weeks. The exercise program will be graded and targeted to the person's physical capacity with the goal of slowly advancing the exercise duration or intensity to effect physiological strengthening and increased physical function.
Preparation of the Technetium Tc 99m Sestamibi from the Kit for Preparation of Technetium Tc 99m Sestamibi for Injection is done by the following aseptic procedure:

Boiling Water Bath Procedure

  1. Prior to adding the Sodium Pertechnetate Tc 99m Injection to the vial, inspect the vial carefully for the presence of damage, particularly cracks, and do not use the vial if found. Tear off a radiation symbol and attach it to the neck of the vial.
  2. Waterproof gloves should be worn during the preparation procedure. Remove the plastic disc from the vial and swab the top of the vial closure with alcohol to sanitize the surface.
  3. Place the vial in a suitable radiation shield with a fitted radiation cap.
  4. With a sterile shielded syringe, aseptically obtain additive-free, sterile, non-pyrogenic Sodium Pertechnetate Tc 99m Injection [925-5550 MBq, (25–150 mCi)] in approximately 1 to 3 mL.
  5. Aseptically add the Sodium Pertechnetate Tc 99m Injection to the vial in the lead shield. Without withdrawing the needle, remove an equal volume of headspace to maintain atmospheric pressure within the vial.
  6. Shake vigorously, about 5 to 10 quick upward-downward motions.
  7. Remove the vial from the lead shield and place upright in an appropriately shielded and contained boiling water bath, such that the vial is suspended above the bottom of the bath, and boil for 10 minutes. Timing for 10 minutes is begun as soon as the water begins to boil again. Do not allow the boiling water to come in contact with the aluminum crimp.
  8. Remove the vial from the water bath, place in the lead shield and allow to cool for 15 minutes.
  9. Using proper shielding, the vial contents should be visually inspected. Use only if the solution is clear and free of particulate matter and discoloration.
  10. Assay the reaction vial using a suitable radioactivity calibration system. Record the Technetium Tc 99m concentration, total volume, assay time and date, expiration time and lot number on the vial shield label and affix the label to the shield.
  11. Store the reaction vial containing the Technetium Tc 99m Sestamibi at 20-25°C (68-77°F)[See USP] until use; at such time the product should be aseptically withdrawn. Technetium Tc 99m Sestamibi should be used within 6 hours of preparation. The vial contains no preservative.
  12. Note:Adherence to the above product reconstitution instructions is recommended. 
  13. The potential for cracking and significant contamination exists whenever vials containing radioactive material are heated.
  14. Product should be used within 6 hours after preparation.
  15. Final product with radiochemical purity of at least 90% was used in the clinical trials that established safety and effectiveness. The radiochemical purity was determined by the following method.
  16. Sun Pharmaceutical Industries, Inc.’s Kit for the Preparation of Technetium Tc 99m Sestamibi for Injection is not to be used with the Recon-o-Stat™ thermal cycler due to the smaller vial size requirements of this heating device.
Subjects with grades ranging from 4-55 on the Quantitative Global Scarring Grading System (QGSGS)1 will be randomized to receive up to 1cc of Juvéderm Vollure on one side of their face and up to 1cc of Saline on the other. On Day 30, this treatment with the same left-right assignment can be repeated if optimal correction on the active intervention side has not been achieved according to the treating investigator. Subjects will return 24-48 hours after their first treatment to fill out questionnaires, take pictures, and to be assessed by blinded evaluators regarding short term adverse events. Subjects will fill out a 30 day subject diary and also return 30 and 90 days after their last treatment to fill out questionnaires, take pictures, complete the Global Aesthetic Improvement Scale (GAIS), and to be assessed on the QGSGS and for long-term adverse events by blinded evaluators. The subjects will be eligible to receive treatment with Juvéderm Vollure 90 days after their last treatment on the placebo-controlled side if they choose. In addition, at 12 months, 18 months, and 24 months, the subjects will return to fill out questionnaires, take pictures, and to be assessed by blinded evaluators for long-term efficacy.
The invention relates to a Veratrum mengtzeanum Loes. f.-containing blood stasis dissipating and pain relieving duck's egg and a production method thereof. The production method mainly comprises the following steps: 1, preparing a Chinese herbal medicinal immersion liquid; 2, preparing a perfume immersion liquid; and 3, immersing duck's eggs. The Chinese herbal medicinal immersion liquid comprises, by weight, 50 parts of Veratrum mengtzeanum Loes. f., 20 parts of Eranthemum pulchellum, 20 parts of Glabrous Sarcandra Herb, 15 parts of Coniogramme japonica (Thunb.) Diels, 15 parts of Cissus hexangularis Thorel ex Planch., 13 parts of Asian butteflybush root and leaf, 10 parts of Indian nightshade root, 8 parts of Tender Catchweed Bedstraw Herb, 6 parts of Chinese tuliptree bark and 5 parts of Chinese asafetida. The Veratrum mengtzeanum Loes. f.-containing blood stasis dissipating and pain relieving duck's egg can be eaten for a long term to reach the efficacy of dissipating blood stasis and reliving pains, astringing sores and killing pests, and transforming blood stasis and eliminating inflammations; and the production method has the advantages of feasibility, easiness in operation and large-scale production, health care, fast effect, pure natural property, non-toxicity and no side effects.
BACKGROUND: The relationship between postoperative cumulative systemic inflammation and cancer survival needs to be investigated. We developed an approach to the prognostication of postoperative esophageal cancer by establishing low and high cut-off values for the C-reactive protein (CRP) area under the curve (AUC) at 7 and 14 days after esophagectomy.
METHODS: One hundred and twenty-five consecutive patients with biopsy-proven invasive esophageal squamous cell carcinoma (SCC) who underwent esophagectomies were evaluated. Postoperative CRP levels were analyzed for the first 14 days after surgery. The AUC on days 7 and 14 were calculated and compared with clinicopathological features and survival. The cut-off values for CRP at 7 days (CRP 7 d) and 14 days (CRP 14 d) were 599 mg/L and 1153 mg/L, respectively.
RESULTS: The patients in the low CRP 7 d group had significantly better recurrence-free survival (RFS) and overall survival (OS), not that in the low CRP 14d group. The OS rates in the high CRP groups at PODs 1, 3, 10, and 14 were significantly lower than those in the low CRP groups. Postoperative complications were more common in the high CRP groups on PODs 3, 10, and 14. Univariate analyses revealed that pTNM stage, depth of tumor invasion, tumor location, lymph node involvement, and CRP 7 d were significant prognostic factors for both OS and RFS. The Cox proportional hazards model identified pTNM, tumor location, and CRP 7d as independent prognostic factors for the RFS and OS.
CONCLUSIONS: Early prediction of patients with postoperative complications, and adequate management will suppress the elevation of CRP 7 d and further suppress the CRP value in the late postoperative period, which may improve the prognosis of esophageal cancer patients after esophagectomy.